GPX4 and cancer: Although inhibition of either xCT/GSH/GPX4 (by BSO) or xCT-cysteine/CoA/TXNRD2 (by PANKi) alone can be tolerated in cancer cells, their combination leads to synthetic lethality (Figure 3D).